The Union health ministry has proposed amending the New Drugs and Clinical Trials Rules, 2019, to bring antimicrobials under the definition of "new drug," according to a ministry statement issued on Thursday. The draft notification, G.S.R. 983(E) dated November 6, would require manufacturers to obtain permission from the Central Licensing Authority before applying to a state licensing authority for a manufacturing licence.
The ministry said the move is expected to strengthen central regulatory oversight and help ensure the quality, safety and efficacy of antimicrobial products. At present, state authorities grant manufacturing licences for these products. According to persons aware of the matter, the amendment was prompted by concerns that some products were cleared without adequate regulatory scrutiny, including bioavailability/bioequivalence and stability studies. The ministry said substandard or ineffective antimicrobials can contribute to the development and spread of antimicrobial resistance, posing risks to patient safety.
A senior health ministry official said the change will apply prospectively. Licences already granted will remain valid, and existing licence holders will not have to reapply. The official described the proposal as an additional regulatory safeguard against antimicrobial resistance and part of the government's broader efforts to promote responsible use of antimicrobials and safeguard patient safety. The G20 New Delhi Leaders' Declaration also underscored the need to address AMR through a One Health approach.
The draft has been issued to invite objections and suggestions from stakeholders and the public within 30 days before the central government considers it for finalisation.